EA201891264A3 - Антагонисты st2l и способы их применения - Google Patents

Антагонисты st2l и способы их применения

Info

Publication number
EA201891264A3
EA201891264A3 EA201891264A EA201891264A EA201891264A3 EA 201891264 A3 EA201891264 A3 EA 201891264A3 EA 201891264 A EA201891264 A EA 201891264A EA 201891264 A EA201891264 A EA 201891264A EA 201891264 A3 EA201891264 A3 EA 201891264A3
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
application
antagonists
st2l
st2l antagonists
Prior art date
Application number
EA201891264A
Other languages
English (en)
Other versions
EA201891264A2 (ru
Inventor
Карен Даффи
Кэтрин Хили
Роберта Лэмб
Рави Малавия
Майкл Пратта
Натали Фурсов
Цзиньцюань Ло
Майкл Насо
Марк Торнетта
Джон Уилер
Шэн-Дзюн У
ЛеРой Холл
Original Assignee
Янссен Байотек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Байотек, Инк. filed Critical Янссен Байотек, Инк.
Publication of EA201891264A2 publication Critical patent/EA201891264A2/ru
Publication of EA201891264A3 publication Critical patent/EA201891264A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Abstract

Настоящее изобретение относится к антагонистам ST2L, полинуклеотидам, кодирующим антагонисты или их фрагменты, а также к способам получения и использования указанных продуктов.
EA201891264A 2012-04-30 2013-04-29 Антагонисты st2l и способы их применения EA201891264A3 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261640407P 2012-04-30 2012-04-30
US201261640238P 2012-04-30 2012-04-30
US13/798,204 US9090694B2 (en) 2012-04-30 2013-03-13 ST2L antibody antagonists
US13/798,226 US9212227B2 (en) 2012-04-30 2013-03-13 ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions

Publications (2)

Publication Number Publication Date
EA201891264A2 EA201891264A2 (ru) 2018-11-30
EA201891264A3 true EA201891264A3 (ru) 2019-02-28

Family

ID=49477497

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201491996A EA031047B1 (ru) 2012-04-30 2013-04-29 Антагонисты st2l и способы их применения
EA201891264A EA201891264A3 (ru) 2012-04-30 2013-04-29 Антагонисты st2l и способы их применения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201491996A EA031047B1 (ru) 2012-04-30 2013-04-29 Антагонисты st2l и способы их применения

Country Status (37)

Country Link
US (4) US9090694B2 (ru)
EP (2) EP2844292B1 (ru)
JP (3) JP6283354B2 (ru)
KR (2) KR102147140B1 (ru)
CN (2) CN107098973A (ru)
AR (1) AR090909A1 (ru)
AU (2) AU2013256645B2 (ru)
BR (1) BR112014027165A2 (ru)
CA (1) CA2871948C (ru)
CL (1) CL2014002955A1 (ru)
CO (1) CO7240389A2 (ru)
CR (1) CR20140488A (ru)
CY (1) CY1122308T1 (ru)
DK (1) DK2844292T3 (ru)
EA (2) EA031047B1 (ru)
EC (1) ECSP14025178A (ru)
ES (1) ES2755094T3 (ru)
HK (1) HK1208182A1 (ru)
HR (1) HRP20191884T1 (ru)
HU (1) HUE045864T2 (ru)
IL (2) IL235401B (ru)
LT (1) LT2844292T (ru)
MX (2) MX358134B (ru)
MY (1) MY166062A (ru)
NI (1) NI201400125A (ru)
NZ (3) NZ702136A (ru)
PE (1) PE20150641A1 (ru)
PH (2) PH12014502435A1 (ru)
PL (1) PL2844292T3 (ru)
PT (1) PT2844292T (ru)
RS (1) RS59511B1 (ru)
SG (2) SG11201407028WA (ru)
SI (1) SI2844292T1 (ru)
TW (3) TWI687440B (ru)
UA (1) UA118336C2 (ru)
UY (1) UY34774A (ru)
WO (1) WO2013165894A2 (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
DK2506871T3 (da) * 2009-11-30 2017-01-02 Janssen Biotech Inc ANTISTOF-Fc-MUTANTER MED ABLATEREDE EFFEKTORFUNKTIONER
US9090694B2 (en) * 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
JP6404314B2 (ja) 2013-03-15 2018-10-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−３３拮抗薬とその使用法
SG10201805934RA (en) 2014-01-10 2018-08-30 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
WO2015164354A1 (en) 2014-04-21 2015-10-29 The Childen's Hospital Of Philadelphia Compositions and methods for treating cytokine-related disorders
EP3157634B1 (en) * 2014-06-23 2018-12-12 Bionomics, Inc. Antibodies that bind lgr4
US10093730B2 (en) 2014-11-10 2018-10-09 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
JP7231326B2 (ja) 2014-11-10 2023-03-01 ジェネンテック， インコーポレイテッド Ｉｌ－３３媒介性障害のための治療及び診断方法
AU2016226415B2 (en) * 2015-03-02 2021-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a TNF receptor 2 antagonist
JP7114460B2 (ja) * 2015-06-26 2022-08-08 サノフィ・バイオテクノロジー モノクローナル抗ＩＬ－１ＲＡｃＰ抗体
SG11201805900YA (en) * 2016-01-14 2018-08-30 Anaptysbio Inc Inhibition of allergic reaction using an il-33 inhibitor
US20190202907A1 (en) * 2016-09-02 2019-07-04 180 Therapeutics Lp Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody
US20190225682A1 (en) * 2016-09-02 2019-07-25 180 Therapeutics Lp Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody
JOP20190093A1 (ar) 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
TW202332696A (zh) 2016-12-01 2023-08-16 美商再生元醫藥公司 治療發炎症狀的方法
CN110494453B (zh) 2017-02-10 2023-05-26 豪夫迈·罗氏有限公司 抗类胰蛋白酶抗体、其组合物及其用途
SG11201909457XA (en) 2017-04-13 2019-11-28 Regeneron Pharma Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
MA51741A (fr) 2018-02-09 2021-05-19 Hoffmann La Roche Procédés thérapeutiques et de diagnostic pour des maladies inflammatoires médiées par des mastocytes
IL307286A (en) 2018-04-11 2023-11-01 Regeneron Pharma Methods and preparations for quantification of IL-33
CN113286814A (zh) * 2018-10-31 2021-08-20 德里尼亚公司 多价调节性t细胞调节子
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
CN110045131B (zh) * 2019-06-14 2019-09-03 迈威(上海)生物科技有限公司 用于测定人il-33/st2通路抑制剂的生物学活性的方法
CA3158323A1 (en) 2019-11-04 2021-05-14 Medimmune Limited Methods of using il-33 antagonists
WO2021089559A1 (en) 2019-11-04 2021-05-14 Medimmune Limited Anti il-33 therapeutic agent fpr treating renal disorders
MX2022011156A (es) 2020-03-13 2022-10-13 Genentech Inc Anticuerpos anti-interleucina-33 y usos de estos.
US20230110203A1 (en) 2020-03-13 2023-04-13 Medimmune Limited Therapeutic methods for the treatment of subjects with risk alelles in il33
WO2021204707A1 (en) 2020-04-06 2021-10-14 Medimmune Limited Treating acute respiratory distress syndrome with il-33 axis binding antagonists
MX2022014243A (es) 2020-05-12 2022-12-02 Chia Tai Tianqing Pharmaceutical Group Co Ltd Proteina de union al antigeno st2.
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
WO2023086807A1 (en) 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2023160610A1 (en) * 2022-02-24 2023-08-31 Sinomab Bioscience Limited Bispecific binding proteins against alarmins and uses thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
AU690171B2 (en) 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
DE69738806D1 (de) 1996-10-10 2008-08-14 Invitrogen Corp Tierzellkulturmedium mit pflanzlichen nährstoffen
GB9727172D0 (en) 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
US6323334B1 (en) * 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
WO2001070817A1 (fr) 2000-03-21 2001-09-27 Medical & Biological Laboratories Co., Ltd. Anticorps monoclonal et methode et kit d'immunodosage de st2 humaine soluble l'utilisant
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
EP2357187A1 (en) * 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US6649055B1 (en) 2002-05-07 2003-11-18 The United States Of America As Represented By The United States Department Of Energy Pump station for radioactive waste water
JP4794301B2 (ja) 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
EP1718602A4 (en) * 2004-01-30 2007-12-12 Peplin Biolipids Pty Ltd THERAPEUTIC AND CARRIER MOLECULES
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
CA2587627A1 (en) 2004-11-15 2006-05-26 Eli Lilly And Company Desacyl ghrelin antibodies and therapeutic uses thereof
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
PL1999154T3 (pl) 2006-03-24 2013-03-29 Merck Patent Gmbh Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
AU2007285855B2 (en) 2006-08-18 2013-03-07 Novartis Ag PRLR-specific antibody and uses thereof
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
EP2069784A4 (en) * 2007-05-18 2009-11-18 Medimmune Llc IL-33 IN INFLAMMATORY DISEASE
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
CA2709847C (en) 2008-01-07 2018-07-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
KR20110014607A (ko) 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
CA2744235A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US8817596B2 (en) 2009-01-09 2014-08-26 Futurewei Technologies, Inc. Protecting ingress and egress of a label switched path
US7879978B2 (en) * 2009-03-31 2011-02-01 Centocor Ortho Biotech, Inc. Macaca fascicularis ST2L
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
DK2506871T3 (da) * 2009-11-30 2017-01-02 Janssen Biotech Inc ANTISTOF-Fc-MUTANTER MED ABLATEREDE EFFEKTORFUNKTIONER
US20110206672A1 (en) 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
JP5887337B2 (ja) 2010-03-30 2016-03-16 ヤンセン バイオテツク，インコーポレーテツド ヒト化ｉｌ−２５抗体
CA2795200C (en) 2010-04-09 2020-01-14 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
MX353144B (es) 2010-04-20 2017-12-20 Genmab As Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
JP6126991B2 (ja) 2010-09-27 2017-05-10 ヤンセン バイオテツク，インコーポレーテツド ヒトｉｉ型コラーゲンに結合する抗体
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
US8785153B2 (en) 2011-02-23 2014-07-22 Hoffmann-La Roche, Inc. Antibodies against human IL33R and uses thereof
US9090694B2 (en) * 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2

Also Published As

Publication number Publication date
IL254569B (en) 2020-10-29
IL254569A0 (en) 2017-11-30
PH12014502435A1 (en) 2015-01-12
US20170066831A1 (en) 2017-03-09
EP2844292A2 (en) 2015-03-11
EP2844292B1 (en) 2019-08-21
JP2015516817A (ja) 2015-06-18
SG11201407028WA (en) 2015-01-29
JP2019162136A (ja) 2019-09-26
AU2017202610B9 (en) 2019-06-20
KR102147140B1 (ko) 2020-08-25
ECSP14025178A (es) 2015-08-31
EA031047B1 (ru) 2018-11-30
CL2014002955A1 (es) 2015-01-16
TW201345923A (zh) 2013-11-16
CN107098973A (zh) 2017-08-29
AU2017202610B2 (en) 2019-06-13
TWI589588B (zh) 2017-07-01
JP6622274B2 (ja) 2019-12-18
LT2844292T (lt) 2019-11-25
HRP20191884T1 (hr) 2020-02-07
TWI700299B (zh) 2020-08-01
CR20140488A (es) 2015-01-12
HUE045864T2 (hu) 2020-01-28
IL235401A0 (en) 2014-12-31
MX358134B (es) 2018-08-06
PH12018501839A1 (en) 2020-09-14
MX2018009430A (es) 2020-09-02
US9212227B2 (en) 2015-12-15
UA118336C2 (uk) 2019-01-10
TW201730216A (zh) 2017-09-01
TW202019969A (zh) 2020-06-01
AR090909A1 (es) 2014-12-17
CA2871948A1 (en) 2013-11-07
EP3597219A1 (en) 2020-01-22
SG10201608525SA (en) 2016-12-29
EA201891264A2 (ru) 2018-11-30
US9090694B2 (en) 2015-07-28
US20130336980A1 (en) 2013-12-19
SI2844292T1 (sl) 2020-02-28
US20190062439A1 (en) 2019-02-28
MY166062A (en) 2018-05-22
WO2013165894A2 (en) 2013-11-07
ES2755094T3 (es) 2020-04-21
JP2018064560A (ja) 2018-04-26
DK2844292T3 (da) 2019-10-21
MX2014013200A (es) 2014-12-08
CA2871948C (en) 2020-09-08
CN104411333B (zh) 2017-04-26
AU2013256645A1 (en) 2014-11-13
PL2844292T3 (pl) 2020-03-31
RS59511B1 (sr) 2019-12-31
IL235401B (en) 2020-10-29
TWI687440B (zh) 2020-03-11
US9951137B2 (en) 2018-04-24
EP2844292A4 (en) 2016-05-25
US20130287777A1 (en) 2013-10-31
NI201400125A (es) 2016-11-30
NZ729913A (en) 2018-07-27
AU2017202610A1 (en) 2017-05-11
WO2013165894A3 (en) 2014-03-27
US10450377B2 (en) 2019-10-22
UY34774A (es) 2013-11-29
HK1208182A1 (en) 2016-02-26
CY1122308T1 (el) 2021-01-27
EA201491996A1 (ru) 2015-04-30
CN104411333A (zh) 2015-03-11
CO7240389A2 (es) 2015-04-17
PT2844292T (pt) 2019-11-26
PE20150641A1 (es) 2015-05-11
KR20150008152A (ko) 2015-01-21
AU2013256645B2 (en) 2017-06-08
NZ702136A (en) 2017-03-31
KR20200037886A (ko) 2020-04-09
JP6283354B2 (ja) 2018-02-21
NZ740221A (en) 2019-11-29
BR112014027165A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
EA201891264A3 (ru) Антагонисты st2l и способы их применения
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201891093A1 (ru) Антитела, специфически связывающие pd-1, и их применение
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
EA201400875A1 (ru) Антитела к cd47 и способы их применения
EA201590868A1 (ru) Противовирусные соединения
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201492002A1 (ru) Противовирусные соединения
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA202190619A1 (ru) Противовирусные соединения
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
MX349630B (es) Alfa-amilasas.
EA201691568A1 (ru) Твердые фармацевтические композиции антагонистов рецепторов андрогенов
EA201692269A1 (ru) Новые композиции, их использование и способы получения
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201591380A1 (ru) АНТАГОНИСТЫ Kv1.3 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
EA201890434A1 (ru) Антитела к cd154 и способы их применения
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
PH12016500598A1 (en) Protoxin-ii variants and methods of use
EA201791312A1 (ru) Способы мечения библиотек, кодируемых днк
EA201690942A1 (ru) Антитела к ccl17